Can a new drug offer hope for blood cancers when chemo fails?

NCT ID NCT04827719

Completed Disease control Sponsor: Groupe Francophone des Myelodysplasies Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called BST-236 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not improved after initial treatment. Participants receive BST-236 as a one-hour intravenous infusion for six days in a row, repeated in cycles. The goal is to see whether this drug can produce a meaningful response in people who are not healthy enough for intensive chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BST-236, an experimental chemotherapy drug given intravenously over six consecutive days per treatment course
What this could lead to: If effective, BST-236 could offer a new treatment option for people with AML or high-risk MDS who have relapsed or not responded to first-line therapy and cannot tolerate intensive chemotherapy.
What could go wrong: This is a small, early-phase (phase 2) study, so success is not guaranteed. The drug may not work well enough or may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

CH Le Mans

Le Mans, 72037, France
CHRU de Limoges - Hôpital Dupuytren

Limoges, 87042, France
CHU Amiens

Amiens, 80054, France
CHU Besançon - Hôpital Jean Minjoz

Besançon, 25030, France
CHU NIMES Caremeau

Nîmes, Nîmes, 30029, France
CHU Nantes - Hôtel Dieu

Nantes, 44093, France
CHU Toulouse - IUCT Oncopole

Toulouse, 31100, France
CHU d'Angers

Angers, 49100, France
CHU de Bordeaux Haut-Lévèque

Bordeaux, 33604, France
CHU de Grenoble

Grenoble, 38700, France
CHU de Nice - Hôpital Archet 1

Nice, 06200, France
CHU de Poitiers

Poitiers, 86021, France
Centre Henri Becquerel

Rouen, Rouen, 76 038, France
Hôpital Pontchaillou

Rennes, 35033, France
Hôpital Saint Louis

Paris, 75010, France
Institut Paoli Calmettes

Marseille, 13009, France
Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.